The UK’s Horizon trial will test a vaccine against the Epstein-Barr virus (EBV), linked to multiple sclerosis, aiming to train the immune system and explore a potential new treatment for MS.
Long-term COVID-19 effects have been decreased from anywhere between 50 and 80% for those who have been vaccinated when compared to unvaccinated people.
Using almost $30 million in funding, an all-in-one vaccine is being developed to bring new protection against a range of new and existing coronavirus variants.